Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC).
Authors
Tsung-Che Wu
National Taiwan University Biomedical Park Hospital, Hsinchu, Taiwan;
Tsung-Che Wu , Yi-Hsin Liang , Kuo-Hsing Chen , Chien Huai Chuang , Yu Yun Shao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 36)
DOI
10.1200/JCO.2023.41.4_suppl.36
Abstract #
36
Poster Bd #
B11
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience.
First Author: Keigo Chida
Poster
2020 Gastrointestinal Cancers Symposium
Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.
First Author: Jun Yin
Poster
2018 Gastrointestinal Cancers Symposium
The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer.
First Author: Akira Okita
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill